

Special Issue

Recent Advances in Antiviral Drug Development

Message from the Guest Editor

Only around 3% of known human viral pathogens are able to be treated with Food and Drug Administration (FDA) approved antivirals, and given these are mostly virus-targeted, drug resistance jeopardizes their efficacy. Further, the COVID-19 pandemic has highlighted major shortfalls and a lack of foresight in drug development against newly emerging viruses. This is why our 'best' option is to repurpose familiar drugs to treat COVID-19 patients. We urgently require new strategies to prevent and treat existing/emerging infections if we are to circumvent future significant health and economic global crises. This Special issue aims to give an overview of the most recent advances in antiviral drug development and new therapeutic targeting strategies. Potential topics include but are not limited to:

- Antiviral drugs;
- Mechanisms of action;
- Perspectives for antiviral drug development;
- Future perspectives for newly emerging viruses;
- Host-targeted therapies;
- Identification of antiviral targets.

Guest Editor

Dr. Natalie Borg

Head, Immunity and Immune Evasion Lab, School of Health and Biomedical Sciences, RMIT University, Bundoora 3083, Australia

Deadline for manuscript submissions

closed (30 April 2023)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/127326

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).